Gilead Sciences Inc. said its two key hepatitis C drugs, Sovaldi and Harvoni, generated about $4.9 billion in sales in the second quarter, topping Wall Street estimates, thanks to better-than-expected […]

What do you get when you combine Obamacare with an expected explosion in the use of pricey drugs and the rapid aging of the Baby Boomer population? The answer, courtesy […]

Twenty-seven years ago George Yancopoulos was a scientific superstar, a professor of biology at Columbia at age 28. But his father, a first-generation Greek immigrant, kept complaining about how little […]

DUBLIN, IRELAND–(Marketwired – Jul 27, 2015) – Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address […]

The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or […]

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.S. Food […]

Latest Approval Expands Product Label in Canada and Further Strengthens Global Brand for Once-Daily, Dual Mechanism Antibiotic DUBLIN, IRELAND–(Marketwired – Jul 23, 2015) – Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance […]

Recently, Vertex received approval for a new two-drug therapy called Orkambi, designed to treat 8,500 cystic fibrosis patients over the age of 12 who have the most common mutation for […]

Update: This morning, Bristol-Myers Squibb announced that its immunotherapy, Opdivo, also delayed cancer progression more than Afinitor in kidney cancer. This raises questions about the sales potential of Exelixis’ drug. […]

The European Commission approval is based upon Phase III clinical trial – Reyataz®(atazanavir) and cobicistat combination demonstrated virologic failure rates as low as 6% at 48 weeks and 8% at […]